Ethyl N-[1-(morpholin-4-yl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carbonyl]carbamate

Catalog No. :
ACLDYZ837
CAS No. :
320420-07-3
Molecular Formula :
C12H16N4O6
Molecular Weight :
312.28

IUPAC Name:ethyl (1-morpholino-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carbonyl)carbamate

Ethyl N-[1-(morpholin-4-yl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carbonyl]carbamate structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
No pack options available.

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product NameEthyl N-[1-(morpholin-4-yl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carbonyl]carbamate
IUPAC Nameethyl (1-morpholino-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carbonyl)carbamate
MDL No.MFCD00172935
Molecular FormulaC12H16N4O6
Molecular Weight312.28
SMILESO=C(OCC)NC(C1=CN(N2CCOCC2)C(NC1=O)=O)=O
InChI KeyAUNLKLQGWAWTGM-UHFFFAOYSA-N
SynonymETHYL N-[(1-MORPHOLINO-2,4-DIOXO-1,2,3,4-TETRAHYDRO-5-PYRIMIDINYL)CARBONYL]CARBAMATE;ethyl N-[1-(morpholin-4-yl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carbonyl]carbamate;Carbamic acid, [[1,2,3,4-tetrahydro-1-(4-morpholinyl)-2,4-dioxo-5-pyrimidinyl]carbonyl]-, ethyl ester (9CI)
CAS No.320420-07-3

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P280-P301+P312-P302+P352-P305+P351+P338

Synthetic Route by SureRoute

1. ACLDYZ837 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACLDYZ837 route product structure diagram
    ACLDYZ837320420-07-3
Inquiry

2. ACLDYZ837 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACLDYZ837 route product structure diagram
    ACLDYZ837320420-07-3
Inquiry

Comments (0)